Trial Profile

Safety of UV1 Vaccination in Combination With Ipilimumab in Patients With Unresectable or Metastatic Malignant Melanoma

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 18 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs UV 1 (Primary) ; Granulocyte macrophage colony stimulating factor; Ipilimumab
Indications Malignant melanoma
Focus Adverse reactions
Sponsors Ultimovacs AS

Most Recent Events

16 Dec 2024 Status changed from active, no longer recruiting to completed.
12 Sep 2022 Results published in the Media Release
12 Sep 2022 According to an Ultimovacs AS media release, data from phase 1 part of this study presented in Journal of Translational Medicine.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com